Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors

por Owen, Dwight H., Otterson, Gregory A.
Publicado 2019

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy

por Petty, Amy J., Owen, Dwight H., Yang, Yiping, Huang, Xiaopei
Publicado 2021

Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records

por Zitu, Md Muntasir, Zhang, Shijun, Owen, Dwight H., Chiang, Chienwei, Li, Lang
Publicado 2023

DLL3: an emerging target in small cell lung cancer

por Owen, Dwight H., Giffin, Michael J., Bailis, Julie M., Smit, Marie-Anne Damiette, Carbone, David P., He, Kai
Publicado 2019

Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers

por Jain, Natasha A, Zhao, Songzhu, Wei, Lai, Rogers, Kerry A, Otterson, Gregory A, Wang, Tzu-Fei, Owen, Dwight H
Publicado 2020

An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations

por Wang, Lei, Wei, Lai, Zhang, Shijun, Cheng, Lijun, Shendre, Aditi, Carson, Williams, Chen, James L., Owen, Dwight, Gregory, Megan, Li, Lang
Publicado 2022

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With None–Small-cell Lung Cancer

por Owen, Dwight H., Wei, Lai, Bertino, Erin M., Edd, Thomas, Villalona-Calero, Miguel A., He, Kai, Shields, Peter G., Carbone, David P., Otterson, Gregory A.
Publicado 2018

Association between immune-related adverse event timing and treatment outcomes

por Hsiehchen, David, Naqash, Abdul Rafeh, Espinoza, Magdalena, Von Itzstein, Mitchell S., Cortellini, Alessio, Ricciuti, Biagio, Owen, Dwight H., Laharwal, Mehak, Toi, Yukihiro, Burke, Michael, Xie, Yang, Gerber, David E.
Publicado 2022

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltrans...

por Owen, Dwight H., Alexander, Andrew J., Konda, Bhavana, Wei, Lai, Hemminger, Jessica A., Schmidt, Carl R., Abdel-Misih, Sherif R.Z., Dillhoff, Mary E., Sipos, Jennifer A., Kirschner, Lawrence S., Shah, Manisha H.
Publicado 2017

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

por Li, Mingjia, Spakowicz, Daniel, Burkart, Jarred, Patel, Sandip, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Carbone, David P., Verschraegen, Claire F., Presley, Carolyn J., Otterson, Gregory A., Kendra, Kari, Owen, Dwight H.
Publicado 2019

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

por Bond, David A, Huang, Ying, Fisher, James L, Ruppert, Amy S, Owen, Dwight H, Bertino, Erin M, Rogers, Kerry A, Bhat, Seema A, Grever, Michael R, Jaglowski, Samantha M, Maddocks, Kami J, Byrd, John C, Woyach, Jennifer A
Publicado 2020

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

por Johns, Andrew C, Yang, Mike, Wei, Lai, Grogan, Madison, Spakowicz, Daniel, Patel, Sandipkumar H, Li, Mingjia, Husain, Marium, Kendra, Kari L, Otterson, Gregory A, Rosko, Ashley E, Andersen, Barbara L, Carbone, David P, Owen, Dwight H, Presley, Carolyn J
Publicado 2023

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

por Haddad, Tyler C., Zhao, Songzhu, Li, Mingjia, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Lopez, Gabriella, Miah, Abdul, Wei, Lai, Tinoco, Gabriel, Riesenberg, Brian, Li, Zihai, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Otterson, Gregory, Presley, Carolyn J., Owen, Dwight H.
Publicado 2021

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

por Abu-Sbeih, Hamzah, Ali, Faisal S., Naqash, Abdul Rafeh, Owen, Dwight H., Patel, Sandipkumar, Otterson, Gregory A., Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K., Wang, Yinghong
Publicado 2019

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

por Spakowicz, Daniel, Hoyd, Rebecca, Muniak, Mitchell, Husain, Marium, Bassett, James S., Wang, Lei, Tinoco, Gabriel, Patel, Sandip H., Burkart, Jarred, Miah, Abdul, Li, Mingjia, Johns, Andrew, Grogan, Madison, Carbone, David P., Verschraegen, Claire F., Kendra, Kari L., Otterson, Gregory A., Li, Lang, Presley, Carolyn J., Owen, Dwight H.
Publicado 2020

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans

por Castillo, Alyssa Marie M., Vu, Trang T., Liva, Sophia G., Chen, Min, Xie, Zhiliang, Thomas, Justin, Remaily, Bryan, Guo, Yizhen, Subrayan, Uma L., Costa, Travis, Helms, Timothy H., Irby, Donald J., Kim, Kyeongmin, Owen, Dwight H., Kulp, Samuel K., Mace, Thomas A., Phelps, Mitch A., Coss, Christopher C.
Publicado 2021

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors

por Matsui, Jennifer K., Perlow, Haley K., Raj, Rohit K., Nalin, Ansel P., Lehrer, Eric J., Kotecha, Rupesh, Trifiletti, Daniel M., McClelland, Shearwood, Kendra, Kari, Williams, Nicole, Owen, Dwight H., Presley, Carolyn J., Thomas, Evan M., Beyer, Sasha J., Blakaj, Dukagjin M., Ahluwalia, Manmeet S., Raval, Raju R., Palmer, Joshua D.
Publicado 2022

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

por Owen, Dwight H., Benner, Brooke, Wei, Lai, Sukrithan, Vineeth, Goyal, Ashima, Zhou, Ye, Pilcher, Carly, Suffren, Sheryl-Ann, Christenson, Gwen, Curtis, Nancy, Jukich, Megan, Schwarz, Emily, Savardekar, Himanshu, Norman, Ruthann, Ferguson, Sarah, Kleiber, Barbara, Wesolowski, Robert, Carson, William E., Otterson, Gregory A., Verschraegen, Claire F., Shah, Manisha H., Konda, Bhavana
Publicado 2023

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

por Subbiah, Vivek, Gainor, Justin F., Oxnard, Geoffrey R., Tan, Daniel S.W., Owen, Dwight H., Cho, Byoung Chul, Loong, Herbert H., McCoach, Caroline E., Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y., Kherani, Jennifer F., Huang, Xin, Kang, Suhyun, Drilon, Alexander
Publicado 2021

The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer

por Thomas, Justin, Torok, Molly A., Agrawal, Kriti, Pfau, Timothy, Vu, Trang T., Lyberger, Justin, Chang, Hsiaochi, Castillo, Alyssa Marie M., Chen, Min, Remaily, Bryan, Kim, Kyeongmin, Xie, Zhiliang, Dillhoff, Mary E., Kulp, Samuel K., Behbehani, Gregory K., Cruz-Monserrate, Zobeida, Ganesan, Latha P., Owen, Dwight H., Phelps, Mitch A., Coss, Christopher C., Mace, Thomas A.
Publicado 2022